Cargando…

Establishment and Characterization of a New Intrahepatic Cholangiocarcinoma Cell Line Resistant to Gemcitabine

Intrahepatic cholangiocarcinoma (ICC) is one of the most lethal liver cancers. Late diagnosis and chemotherapy resistance contribute to the scarce outfit and poor survival. Resistance mechanisms are still poorly understood. Here, we established a Gemcitabine (GEM) resistant model, the MT-CHC01R1.5 c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varamo, Chiara, Peraldo-Neia, Caterina, Ostano, Paola, Basiricò, Marco, Raggi, Chiara, Bernabei, Paola, Venesio, Tiziana, Berrino, Enrico, Aglietta, Massimo, Leone, Francesco, Cavalloni, Giuliana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520787/ https://www.ncbi.nlm.nih.gov/pubmed/30979003 http://dx.doi.org/10.3390/cancers11040519

Ejemplares similares

A Novel Multidrug-Resistant Cell Line from an Italian Intrahepatic Cholangiocarcinoma Patient
por: Peraldo-Neia, Caterina, et al.
Publicado: (2021)

Paclitaxel Restores Sensitivity to Chemotherapy in Preclinical Models of Multidrug-Resistant Intrahepatic Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2022)

Establishment and characterization of a human intrahepatic cholangiocarcinoma cell line derived from an Italian patient
por: Cavalloni, Giuliana, et al.
Publicado: (2015)

Gene and microRNA modulation upon trabectedin treatment in a human intrahepatic cholangiocarcinoma paired patient derived xenograft and cell line
por: Peraldo Neia, Caterina, et al.
Publicado: (2016)

Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation
por: Cavalloni, Giuliana, et al.
Publicado: (2016)

Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients
por: Peraldo-Neia, Caterina, et al.
Publicado: (2019)

Evolution of the Experimental Models of Cholangiocarcinoma
por: Massa, Annamaria, et al.
Publicado: (2020)

Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma
por: Cavalloni, Giuliana, et al.
Publicado: (2016)

Proteomic analysis identifies deregulated metabolic and oxidative-associated proteins in Italian intrahepatic cholangiocarcinoma patients
por: Cavalloni, Giuliana, et al.
Publicado: (2021)

Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma
por: Peraldo-Neia, C., et al.
Publicado: (2018)

Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: a prospective observational trial (CHECKPOINT)
por: Lombardi, Pasquale, et al.
Publicado: (2022)

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
por: Pignochino, Ymera, et al.
Publicado: (2010)

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR
por: Peraldo-Neia, Caterina, et al.
Publicado: (2018)

Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models
por: Peraldo-Neia, Caterina, et al.
Publicado: (2014)

Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer
por: Peraldo-Neia, Caterina, et al.
Publicado: (2011)

Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma
por: Ostano, Paola, et al.
Publicado: (2020)

The protease‐inhibitor SerpinB3 as a critical modulator of the stem‐like subset in human cholangiocarcinoma
por: Correnti, Margherita, et al.
Publicado: (2021)

Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy
por: Kinzler, Maximilian N., et al.
Publicado: (2022)

Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma
por: Ishii, Masatsugu, et al.
Publicado: (2022)

Sulforaphane Potentiates Gemcitabine-Mediated Anti-Cancer Effects against Intrahepatic Cholangiocarcinoma by Inhibiting HDAC Activity
por: Tomooka, Fumimasa, et al.
Publicado: (2023)

Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma
por: Franssen, Stijn, et al.
Publicado: (2023)

Cold Formalin Fixation Guarantees DNA Integrity in Formalin Fixed Paraffin Embedded Tissues: Premises for a Better Quality of Diagnostic and Experimental Pathology With a Specific Impact on Breast Cancer
por: Berrino, Enrico, et al.
Publicado: (2020)

Free episomal and integrated HBV DNA in HBsAg-negative patients with intrahepatic cholangiocarcinoma
por: Pollicino, Teresa, et al.
Publicado: (2019)

Intrahepatic Sarcomatoid Cholangiocarcinoma
por: Malhotra, Shalini, et al.
Publicado: (2010)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Management of Intrahepatic Cholangiocarcinoma
por: Kodali, Sudha, et al.
Publicado: (2021)

Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients
por: Berrino, Enrico, et al.
Publicado: (2021)

Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study
por: Zhang, Yu-Qing, et al.
Publicado: (2023)

Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?
por: Bourien, Héloïse, et al.
Publicado: (2023)

Saikosaponin D reverses epinephrine- and norepinephrine-induced gemcitabine resistance in intrahepatic cholangiocarcinoma by downregulating ADRB2/glycolysis signaling: Saikosaponin D reverses gemcitabine resistance
por: He, Hui, et al.
Publicado: (2023)

Establishment and Characterization of a New Human Intrahepatic Cholangiocarcinoma Cell Line LIV27
por: Ding, Xiwei, et al.
Publicado: (2022)

Stereotactic radiotherapy in intrahepatic cholangiocarcinoma: A systematic review
por: Bisello, Silvia, et al.
Publicado: (2021)

Two Varieties of Intrahepatic Cholangiocarcinoma
por: Nagorney, David M.
Publicado: (1994)

Intrahepatic Cholangiocarcinoma with Sarcomatous Changes
por: Inoue, Yoshiyuki, et al.
Publicado: (2012)

Serum Markers of Intrahepatic Cholangiocarcinoma
por: Malaguarnera, Giulia, et al.
Publicado: (2013)

Intrahepatic cholangiocarcinoma: current perspectives
por: Buettner, Stefan, et al.
Publicado: (2017)

Intratumoral heterogeneity of intrahepatic cholangiocarcinoma
por: Walter, Dirk, et al.
Publicado: (2017)

Molecular heterogeneity in intrahepatic cholangiocarcinoma
por: Ahn, Keun Soo, et al.
Publicado: (2020)

Recurrent Intrahepatic Cholangiocarcinoma – Review
por: Bekki, Yuki, et al.
Publicado: (2021)

Stereotactic radiotherapy for intrahepatic cholangiocarcinoma
por: Borakati, Aditya, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ulfmc3gklk6t2su9dp0ruk4obm